Worldwide, more than 1600 infants become infected with HIV each day. Almost all infections are a result of mother-to-child transmission of HIV, with most of these infections occurring in resource-poor countries. In developed countries, antiretroviral prophylaxis has dramatically reduced perinatal transmission to <2%. The potential now exists to extend this success to resource-poor countries using effective but shorter and less expensive antiretroviral regimens.With the potential widespread use of antiretroviral therapy for perinatal HIV prevention in resource-limited settings, there will be exposure of increasing numbers of infants to in utero and postpartum antiretroviral drugs for which long-term toxicity data is unknown. This article focuses on a review of what is known about safety of antiretroviral regimens used to interrupt mother-to-child transmission for women and their children.
Address correspondence and reprint requests to Lynne M. Mofenson, MD, Pediatric, Adolescent and Maternal AIDS Branch, National Institute of Child Health and Human Development National Institutes of Health 6100 Executive Boulevard, Room 4B11 Rockville, MD 20852, U.S.A.; e-mail: LM65D@nih.gov
Manuscript received February 7, 2002; accepted March 28, 2002.
© 2002 Lippincott Williams & Wilkins, Inc.